Showing results (3121-3130 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|November 23, 2020
Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit FrontierChristopher McCabe, Giovanni Tramonti, Andrew Sutton, et al.Pharmacoeconomics|June 20, 2022
Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular DiseaseKatya Galactionova, Paola Salari, Renato Mattli, et al.Pharmacoeconomics|December 27, 2022
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU ChemotherapyChen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, et al.Pharmacoeconomics|November 28, 2022
Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3LJonathan L Nazari, A Simon Pickard, Ning Yan GuPharmacoeconomics|December 5, 2022
How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the GlobeTuba Saygın Avşar, Xiaozhe Yang, Paula LorgellyPharmacoeconomics|July 7, 2021
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and TisagenlecleucelKaren M Facey, Jaime Espin, Emma Kent, et al.Pharmacoeconomics|September 15, 2020
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in ChinaLei Tian, Xiaomo Xiong, Qiang Guo, et al.Pharmacoeconomics|September 3, 2020
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology AppraisalCaroline Farmer, Ash Bullement, David Packman, et al.Pharmacoeconomics|September 29, 2020
Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying TherapiesLuis Hernandez, Malinda O'Donnell, Maarten Postma, et al.Pharmacoeconomics|September 22, 2020
Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient GroupsShweta Mital, Hai V NguyenPageof 336